Status:
COMPLETED
Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Lead Sponsor:
Allergan
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This study will evaluate the safety and efficacy of brimonidine tartrate/timolol fixed combination (Combigan®) compared with brimonidine tartrate (Alphagan®) and timolol in patients with glaucoma or o...
Eligibility Criteria
Inclusion
- Open-angle glaucoma or ocular hypertension in at least one eye that is not responsive to topical beta blockers
- No anticipated wearing of contact lenses during study
Exclusion
- Active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye)
- Any intraocular surgery or laser (eg, cataract surgery or Lasik) within 3 months
- Required regular use of other ocular medications except for occasional use of artificial tears
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
238 Patients enrolled
Trial Details
Trial ID
NCT01229462
Start Date
October 1 2010
End Date
September 1 2011
Last Update
September 14 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou, Guangdong, China